Human Chronic Lymphocytic Leukaemia cells: Untreated vs mithramycin-treated

Transcriptional profiling of primary human malignant B cells from patients with chronic lymphocytic leukaemia (CLL), comparing untreated CLL cells with CLL cells that have been treated 24h with 200nM mithramycin. Mithramycin intercalates into GC-rich regions of DNA to inhibit binding of the transcription factor SP1. The goal of this experiment is to gain understanding of the genes regulated by SP1 in primary CLL cells. Two condition experiment. CLL cells purified from 4 patient samples. Untreated vs mithramycin-treated CLL cells. Biological replicates: 4 (untreated (control) vs treated (mithramycin))